Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Eric L. Nuermberger Clear advanced filters

  • The cytochrome bc1 oxidase of Mycobacterium tuberculosis is a potential target in the fight against tuberculosis. Here, the authors evaluate the potential of cytochrome bc1 inhibitors as partner drugs in tuberculosis treatment regimens.

    • Clara Aguilar-Pérez
    • Anne J. Lenaerts
    • Dirk A. Lamprecht
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-9

  • Therapy of tuberculosis is challenging, mainly due to complex structures of necrotic granulomas that often impair drug delivery. In this work, the authors show that the drug BTZ-043 fully penetrates necrotic granulomas and has potent lesional antibacterial activity.

    • Andreas Römpp
    • Axel Treu
    • Kerstin Walter
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-15

  • Tuberculosis is a major cause of mortality, and the rise of drug-resistant strains of Mycobacterium tuberculosis requires the urgent development of safe and effective treatments. In this work, the authors develop a compound against lysyl-tRNA synthetase, demonstrating on-target mechanism of action and efficacy in vivo.

    • Simon R. Green
    • Susan H. Davis
    • Laura A. T. Cleghorn
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-12

  • Batchelder et al. report a new penem class antibiotic, T405, which exhibits potent activity against M. abscessus and clinical isolates from cystic fibrosis patients. The development of resistance to T405 is inhibited with the addition of a β-lactamase inhibitor, avibactam. Its clinical potential is further demonstrated by T405 displaying a favourable pharmacokinetic profile in mice with an absence of toxicity.

    • Hunter R. Batchelder
    • Elizabeth Story-Roller
    • Craig A. Townsend
    ResearchOpen Access
    Communications Biology
    Volume: 3, P: 1-5

  • After many lean years, important progress has been made in updating the anti-tuberculosis drug armamentarium; a new drug that targets bacterial protein synthesis is one of several that could help transform the treatment of this neglected and deadly disease.

    • Eric L. Nuermberger
    • Richard E. Chaisson
    News & Views
    Nature Medicine
    Volume: 30, P: 642-643

  • Authors perform an analysis of the patient data and risk factors to evaluate unfavorable outcomes and adverse events in adults with pulmonary tuberculosis treated with a 4-month rifapentine based regimen. Low rifapentine exposure was the most clinically significant risk factor for treatment failure and tuberculosis relapse.

    • Vincent K. Chang
    • Marjorie Z. Imperial
    • Elizabeth Guy
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-12